Do analysts recommend CUE or GRCE?

Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 148.34%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Grace Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, GRCE or NGEN?

NervGen Pharma is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$7.79M -$0.48 N/A NervGen Pharma N/A N/A N/A -$0.09 N/A

Is GRCE or NGEN more profitable?

NervGen Pharma's return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -14.45% -13.58% NervGen Pharma N/A N/A N/A

Grace Therapeutics (GRCE) Competitors

$2.42 +0.01 (+0.25%)

As of 12:01 PM Eastern

Compare

GRCE vs. IMDX, HUMA, CUE, ASRT, and NGEN

Should you buy Grace Therapeutics stock or one of its competitors? MarketBeat compares Grace Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Grace Therapeutics include Oncocyte (IMDX), Humacyte (HUMA), Cue Biopharma (CUE), Assertio (ASRT), and NervGen Pharma (NGEN). These companies are all part of the "pharmaceutical products" industry.

How does Grace Therapeutics compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Grace Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Grace Therapeutics	N/A	-14.45%	-13.58%

Grace Therapeutics has lower revenue, but higher earnings than Oncocyte. Grace Therapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	38.27	-$50.22M	-$1.48	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

In the previous week, Oncocyte had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 2 mentions for Oncocyte and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.90 beat Oncocyte's score of 0.93 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncocyte	Positive
Grace Therapeutics	Very Positive

Oncocyte currently has a consensus price target of $12.00, indicating a potential upside of 150.00%. Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 148.34%. Given Oncocyte's higher probable upside, equities analysts clearly believe Oncocyte is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oncocyte has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Summary

Oncocyte beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to Humacyte?

Humacyte (NASDAQ:HUMA) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Grace Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Grace Therapeutics' return on equity of -14.45% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Grace Therapeutics	N/A	-14.45%	-13.58%

Humacyte currently has a consensus price target of $6.25, suggesting a potential upside of 857.12%. Grace Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 148.34%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Humacyte had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 4 mentions for Humacyte and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.90 beat Humacyte's score of 0.94 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Positive
Grace Therapeutics	Very Positive

44.7% of Humacyte shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Humacyte has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Grace Therapeutics has lower revenue, but higher earnings than Humacyte. Grace Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	71.07	-$40.83M	-$0.57	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

Summary

Humacyte beats Grace Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Grace Therapeutics compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, Cue Biopharma had 4 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Cue Biopharma and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.90 beat Cue Biopharma's score of 0.56 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cue Biopharma	Positive
Grace Therapeutics	Very Positive

Grace Therapeutics has lower revenue, but higher earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.66	-$26.60M	-$5.58	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 148.34%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Grace Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Grace Therapeutics' return on equity of -14.45% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Grace Therapeutics	N/A	-14.45%	-13.58%

Cue Biopharma has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Summary

Grace Therapeutics beats Cue Biopharma on 10 of the 15 factors compared between the two stocks.

How does Grace Therapeutics compare to Assertio?

Assertio (NASDAQ:ASRT) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Assertio presently has a consensus target price of $22.65, indicating a potential downside of 3.62%. Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 148.34%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Assertio had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 2 mentions for Assertio and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.90 beat Assertio's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Assertio	Neutral
Grace Therapeutics	Very Positive

Assertio has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Grace Therapeutics has lower revenue, but higher earnings than Assertio. Grace Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

Grace Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Grace Therapeutics' return on equity of -14.45% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Grace Therapeutics	N/A	-14.45%	-13.58%

49.0% of Assertio shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 5.7% of Assertio shares are owned by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Grace Therapeutics beats Assertio on 9 of the 15 factors compared between the two stocks.

How does Grace Therapeutics compare to NervGen Pharma?

Grace Therapeutics (NASDAQ:GRCE) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

6.1% of Grace Therapeutics shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NervGen Pharma is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

In the previous week, NervGen Pharma had 14 more articles in the media than Grace Therapeutics. MarketBeat recorded 15 mentions for NervGen Pharma and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.90 beat NervGen Pharma's score of -0.18 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Grace Therapeutics	Very Positive
NervGen Pharma	Neutral

NervGen Pharma's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-14.45%	-13.58%
NervGen Pharma	N/A	N/A	N/A

Grace Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 148.34%. NervGen Pharma has a consensus price target of $14.00, indicating a potential upside of 746.43%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NervGen Pharma is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

NervGen Pharma beats Grace Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRCE vs. The Competition

Export

Metric	Grace Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$39.33M	$3.69B	$6.87B	$12.28B
Dividend Yield	N/A	2.20%	2.68%	8.87%
P/E Ratio	-5.04	21.35	27.22	23.92
Price / Sales	N/A	305.18	581.69	113.21
Price / Cash	N/A	146.26	49.25	59.89
Price / Book	0.58	8.41	10.72	6.21
Net Income	-$7.79M	$23.83M	$3.59B	$331.73M
7 Day Performance	-1.39%	-3.35%	-2.12%	-2.18%
1 Month Performance	8.83%	3.50%	2.12%	-1.53%
1 Year Performance	-27.88%	44.65%	24.56%	16.99%

Grace Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRCE Grace Therapeutics	2.7401 of 5 stars	$2.42 +0.2%	$6.00 +148.3%	-27.8%	$39.33M	N/A	N/A	N/A
IMDX Oncocyte	3.088 of 5 stars	$5.08 +4.7%	$12.00 +136.2%	N/A	$156.61M	$4.05M	N/A	120	News Coverage
HUMA Humacyte	4.0862 of 5 stars	$0.69 -0.9%	$6.25 +801.0%	-72.4%	$155.48M	$2.04M	N/A	150
CUE Cue Biopharma	0.2834 of 5 stars	$36.78 +0.7%	N/A	-96.4%	$153.35M	$27.47M	N/A	60	Gap Down High Trading Volume
ASRT Assertio	1.5494 of 5 stars	$23.50 flat	$22.65 -3.6%	N/A	$151.81M	$118.71M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRCE) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grace Therapeutics (GRCE) Competitors

GRCE vs. IMDX, HUMA, CUE, ASRT, and NGEN

How does Grace Therapeutics compare to Oncocyte?

Summary

How does Grace Therapeutics compare to Humacyte?

Summary

How does Grace Therapeutics compare to Cue Biopharma?

Summary

How does Grace Therapeutics compare to Assertio?

Summary

How does Grace Therapeutics compare to NervGen Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grace Therapeutics (GRCE) Competitors

GRCE vs. IMDX, HUMA, CUE, ASRT, and NGEN

How does Grace Therapeutics compare to Oncocyte?

Do insiders & institutionals believe in IMDX or GRCE?

Is IMDX or GRCE more profitable?

Which has higher valuation & earnings, IMDX or GRCE?

Does the media prefer IMDX or GRCE?

Do analysts rate IMDX or GRCE?

Which has more volatility & risk, IMDX or GRCE?

Summary

How does Grace Therapeutics compare to Humacyte?

Is HUMA or GRCE more profitable?

Do analysts rate HUMA or GRCE?

Does the media refer more to HUMA or GRCE?

Do insiders and institutionals have more ownership in HUMA or GRCE?

Which has more risk & volatility, HUMA or GRCE?

Which has higher earnings & valuation, HUMA or GRCE?

Summary

How does Grace Therapeutics compare to Cue Biopharma?

Does the media refer more to CUE or GRCE?

Which has preferable valuation & earnings, CUE or GRCE?

Do analysts recommend CUE or GRCE?

Do insiders & institutionals have more ownership in CUE or GRCE?

Is CUE or GRCE more profitable?

Which has more volatility & risk, CUE or GRCE?

Summary

How does Grace Therapeutics compare to Assertio?

Do analysts rate ASRT or GRCE?

Does the media refer more to ASRT or GRCE?

Which has more risk and volatility, ASRT or GRCE?

Which has higher earnings & valuation, ASRT or GRCE?

Is ASRT or GRCE more profitable?

Do institutionals & insiders believe in ASRT or GRCE?

Summary

How does Grace Therapeutics compare to NervGen Pharma?

Do institutionals and insiders have more ownership in GRCE or NGEN?

Which has stronger earnings & valuation, GRCE or NGEN?

Does the media favor GRCE or NGEN?

Is GRCE or NGEN more profitable?

Do analysts prefer GRCE or NGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools